# Boston Scientific Corp: financial statements, quarterly

BSX · NYSE · CIK 885725 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bsx.md) · [Financials](/companies/bsx/financials.md) · [Filings](/companies/bsx/filings.md) · [Insiders](/companies/bsx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bsx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [3,527](/filings/0000885725-24-000073.md) | [3,725 d](/filings/0000885725-26-000010.md) | [3,856](/filings/0000885725-25-000026.md) | [4,120](/filings/0000885725-25-000041.md) | [4,209](/filings/0000885725-25-000050.md) | [4,561 d](/filings/0000885725-26-000010.md) | [4,663](/filings/0000885725-26-000033.md) | [5,061](/filings/0000885725-26-000053.md) | [5,065](/filings/0000885725-25-000050.md) | [5,286 d](/filings/0000885725-26-000010.md) | [5,203](/filings/0000885725-26-000033.md) | [5,442](/filings/0000885725-26-000053.md) |
| Cost of revenue | $m | [1,101](/filings/0000885725-24-000073.md) | [1,147 d](/filings/0000885725-26-000010.md) | [1,209](/filings/0000885725-25-000026.md) | [1,270](/filings/0000885725-25-000041.md) | [1,312](/filings/0000885725-25-000050.md) | [1,466 d](/filings/0000885725-26-000010.md) | [1,453](/filings/0000885725-26-000033.md) | [1,637](/filings/0000885725-26-000053.md) | [1,523](/filings/0000885725-25-000050.md) | [1,608 d](/filings/0000885725-26-000010.md) | [1,590](/filings/0000885725-26-000033.md) | [1,594](/filings/0000885725-26-000053.md) |
| Gross profit | $m | [2,426](/filings/0000885725-24-000073.md) | [2,579 d](/filings/0000885725-26-000010.md) | [2,648](/filings/0000885725-25-000026.md) | [2,850](/filings/0000885725-25-000041.md) | [2,897](/filings/0000885725-25-000050.md) | [3,095 d](/filings/0000885725-26-000010.md) | [3,210](/filings/0000885725-26-000033.md) | [3,424](/filings/0000885725-26-000053.md) | [3,542](/filings/0000885725-25-000050.md) | [3,679 d](/filings/0000885725-26-000010.md) | [3,614](/filings/0000885725-26-000033.md) | [3,848](/filings/0000885725-26-000053.md) |
| Selling, general and administrative | $m | [1,242](/filings/0000885725-24-000073.md) | [1,379 d](/filings/0000885725-26-000010.md) | [1,364](/filings/0000885725-25-000026.md) | [1,446](/filings/0000885725-25-000041.md) | [1,562](/filings/0000885725-25-000050.md) | [1,612 d](/filings/0000885725-26-000010.md) | [1,597](/filings/0000885725-26-000033.md) | [1,716](/filings/0000885725-26-000053.md) | [1,741](/filings/0000885725-25-000050.md) | [1,834 d](/filings/0000885725-26-000010.md) | [1,781](/filings/0000885725-26-000033.md) | [1,803](/filings/0000885725-26-000053.md) |
| Operating income | $m | [693](/filings/0000885725-24-000073.md) | [584 d](/filings/0000885725-26-000010.md) | [675](/filings/0000885725-25-000026.md) | [520](/filings/0000885725-25-000041.md) | [733](/filings/0000885725-25-000050.md) | [675 d](/filings/0000885725-26-000010.md) | [921](/filings/0000885725-26-000033.md) | [819](/filings/0000885725-26-000053.md) | [1,048](/filings/0000885725-25-000050.md) | [825 d](/filings/0000885725-26-000010.md) | [1,101](/filings/0000885725-26-000033.md) | [1,178](/filings/0000885725-26-000053.md) |
| Interest expense | $m | [66.0](/filings/0000885725-24-000073.md) | [65.0 d](/filings/0000885725-26-000010.md) | [69.0](/filings/0000885725-25-000026.md) | [77.0](/filings/0000885725-25-000041.md) | [79.0](/filings/0000885725-25-000050.md) | [80.0 d](/filings/0000885725-26-000010.md) | [82.0](/filings/0000885725-26-000033.md) | [90.0](/filings/0000885725-26-000053.md) | [87.0](/filings/0000885725-25-000050.md) | [90.0 d](/filings/0000885725-26-000010.md) | [90.0](/filings/0000885725-26-000033.md) | [96.0](/filings/0000885725-26-000053.md) |
| Income tax | $m | [105](/filings/0000885725-24-000073.md) | [1.0 d](/filings/0000885725-26-000010.md) | [115](/filings/0000885725-25-000026.md) | [98.0](/filings/0000885725-25-000041.md) | [200](/filings/0000885725-25-000050.md) | [23.0 d](/filings/0000885725-26-000010.md) | [133](/filings/0000885725-26-000033.md) | [146](/filings/0000885725-26-000053.md) | [183](/filings/0000885725-25-000050.md) | [30.0 d](/filings/0000885725-26-000010.md) | [(176)](/filings/0000885725-26-000033.md) | [155](/filings/0000885725-26-000053.md) |
| Net income | $m | [504](/filings/0000885725-24-000073.md) | [504 d](/filings/0000885725-26-000010.md) | [493](/filings/0000885725-25-000026.md) | [322](/filings/0000885725-25-000041.md) | [468](/filings/0000885725-25-000050.md) | [562 d](/filings/0000885725-26-000010.md) | [672](/filings/0000885725-26-000033.md) | [795](/filings/0000885725-26-000053.md) | [755](/filings/0000885725-25-000050.md) | [670 d](/filings/0000885725-26-000010.md) | [1,339](/filings/0000885725-26-000033.md) | [905](/filings/0000885725-26-000053.md) |
| Diluted EPS | $ per share | [0.34](/filings/0000885725-24-000073.md) | not reported | [0.33](/filings/0000885725-25-000026.md) | [0.22](/filings/0000885725-25-000041.md) | [0.32](/filings/0000885725-25-000050.md) | not reported | [0.45](/filings/0000885725-26-000033.md) | [0.53](/filings/0000885725-26-000053.md) | [0.51](/filings/0000885725-25-000050.md) | not reported | [0.90](/filings/0000885725-26-000033.md) | [0.61](/filings/0000885725-26-000053.md) |
| Basic EPS | $ per share | [0.34](/filings/0000885725-24-000073.md) | not reported | [0.34](/filings/0000885725-25-000026.md) | [0.22](/filings/0000885725-25-000041.md) | [0.32](/filings/0000885725-25-000050.md) | not reported | [0.46](/filings/0000885725-26-000033.md) | [0.54](/filings/0000885725-26-000053.md) | [0.51](/filings/0000885725-25-000050.md) | not reported | [0.90](/filings/0000885725-26-000033.md) | [0.62](/filings/0000885725-26-000053.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [1.0](/filings/0000885725-24-000073.md) | [0.9](/filings/0000885725-26-000010.md) | [2.3](/filings/0000885725-25-000026.md) | [2.9](/filings/0000885725-25-000041.md) | [2.5](/filings/0000885725-25-000050.md) | [0.4](/filings/0000885725-26-000010.md) | [0.7](/filings/0000885725-26-000033.md) | [0.5](/filings/0000885725-26-000053.md) | [1.3](/filings/0000885725-25-000050.md) | [2.0](/filings/0000885725-26-000053.md) | [1.5](/filings/0000885725-26-000033.md) | [0.5](/filings/0000885725-26-000053.md) |
| Current assets | $bn | [6.5](/filings/0000885725-23-000048.md) | [6.5](/filings/0000885725-25-000011.md) | [8.2](/filings/0000885725-24-000046.md) | [9.0](/filings/0000885725-24-000068.md) | [8.8](/filings/0000885725-24-000073.md) | [6.9](/filings/0000885725-26-000010.md) | [7.3](/filings/0000885725-25-000026.md) | [7.1](/filings/0000885725-25-000041.md) | [8.0](/filings/0000885725-25-000050.md) | [8.8](/filings/0000885725-26-000053.md) | [8.7](/filings/0000885725-26-000033.md) | [8.0](/filings/0000885725-26-000053.md) |
| Total assets | $bn | [34.0](/filings/0000885725-23-000048.md) | [35.1](/filings/0000885725-25-000011.md) | [36.7](/filings/0000885725-24-000046.md) | [37.1](/filings/0000885725-24-000068.md) | [38.1](/filings/0000885725-24-000073.md) | [39.4](/filings/0000885725-26-000010.md) | [40.1](/filings/0000885725-25-000026.md) | [41.6](/filings/0000885725-25-000041.md) | [42.7](/filings/0000885725-25-000050.md) | [43.7](/filings/0000885725-26-000053.md) | [44.4](/filings/0000885725-26-000033.md) | [45.2](/filings/0000885725-26-000053.md) |
| Current liabilities | $bn | [4.6](/filings/0000885725-23-000048.md) | [4.9](/filings/0000885725-25-000011.md) | [4.9](/filings/0000885725-24-000046.md) | [5.6](/filings/0000885725-24-000068.md) | [5.9](/filings/0000885725-24-000073.md) | [6.4](/filings/0000885725-26-000010.md) | [5.1](/filings/0000885725-25-000026.md) | [5.2](/filings/0000885725-25-000041.md) | [5.3](/filings/0000885725-25-000050.md) | [5.4](/filings/0000885725-26-000053.md) | [4.6](/filings/0000885725-26-000033.md) | [6.4](/filings/0000885725-26-000053.md) |
| Long-term debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $bn | [0.5](/filings/0000885725-23-000048.md) | [0.5](/filings/0000885725-25-000011.md) | [1.1](/filings/0000885725-24-000046.md) | [1.6](/filings/0000885725-24-000068.md) | [1.7](/filings/0000885725-24-000073.md) | [1.8](/filings/0000885725-26-000010.md) | [0.8](/filings/0000885725-25-000026.md) | [0.5](/filings/0000885725-25-000041.md) | [0.5](/filings/0000885725-25-000050.md) | [0.3](/filings/0000885725-26-000053.md) | [0.0](/filings/0000885725-26-000033.md) | [1.7](/filings/0000885725-26-000053.md) |
| Shareholders' equity | $bn | [18.9](/filings/0000885725-24-000073.md) | [19.3](/filings/0000885725-25-000011.md) | [19.9](/filings/0000885725-24-000046.md) | [20.4](/filings/0000885725-25-000041.md) | [20.7](/filings/0000885725-25-000050.md) | [21.8](/filings/0000885725-26-000010.md) | [22.2](/filings/0000885725-25-000026.md) | [22.4](/filings/0000885725-26-000053.md) | [23.4](/filings/0000885725-25-000050.md) | [24.2](/filings/0000885725-26-000053.md) | [25.9](/filings/0000885725-26-000033.md) | [24.9](/filings/0000885725-26-000053.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: not reported
- Current portion of debt: us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [698 d](/filings/0000885725-24-000073.md) | [957 d](/filings/0000885725-26-000010.md) | [164](/filings/0000885725-25-000026.md) | [813 d](/filings/0000885725-25-000041.md) | [1,002 d](/filings/0000885725-25-000050.md) | [1,456 d](/filings/0000885725-26-000010.md) | [541](/filings/0000885725-26-000033.md) | [1,286 d](/filings/0000885725-26-000053.md) | [1,343 d](/filings/0000885725-25-000050.md) | [1,364 d](/filings/0000885725-26-000010.md) | [348](/filings/0000885725-26-000033.md) | [1,474 d](/filings/0000885725-26-000053.md) |
| Capital expenditure | $m | [190 d](/filings/0000885725-24-000073.md) | [267 d](/filings/0000885725-26-000010.md) | [179](/filings/0000885725-25-000026.md) | [155 d](/filings/0000885725-25-000041.md) | [179 d](/filings/0000885725-25-000050.md) | [277 d](/filings/0000885725-26-000010.md) | [187](/filings/0000885725-26-000033.md) | [157 d](/filings/0000885725-26-000053.md) | [181 d](/filings/0000885725-25-000050.md) | [351 d](/filings/0000885725-26-000010.md) | [177](/filings/0000885725-26-000033.md) | [195 d](/filings/0000885725-26-000053.md) |
| Dividends paid | $m | [0.0 d](/filings/0000885725-24-000073.md) | [0.0 d](/filings/0000885725-25-000011.md) | [0.0](/filings/0000885725-24-000046.md) | [0.0 d](/filings/0000885725-24-000068.md) | [0.0 d](/filings/0000885725-24-000073.md) | [0.0 d](/filings/0000885725-25-000011.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1,440](/filings/0000885725-23-000048.md) | [1,446](/filings/0000885725-24-000046.md) | [1,456](/filings/0000885725-24-000068.md) | [1,475](/filings/0000885725-24-000073.md) | [1,482](/filings/0000885725-25-000026.md) | [1,484](/filings/0000885725-25-000041.md) | [1,487](/filings/0000885725-25-000050.md) | [1,493](/filings/0000885725-26-000033.md) | [1,494](/filings/0000885725-26-000053.md) | [1,496](/filings/0000885725-25-000050.md) | [1,495](/filings/0000885725-26-000033.md) | [1,475](/filings/0000885725-26-000053.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,449,229,526 at 2026-07-30, from the cover of the [10-Q filed 2026-08-03](/filings/0000885725-26-000053.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.